Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
Oncology
|
July 15, 2005
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
M Scartozzi, A Sobrero, G Gasparini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials
S Cascinu, D Poli, A Zaniboni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2007
First-line single-agent cetuximab in patients with advanced colorectal cancer
A Pessino, S Artale, S Sciallero, et al.
British Journal of Cancer
|
December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
S Cascinu, R Berardi, S Salvagni, et al.
British Journal of Cancer
|
February 14, 1998
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study
C Aschele, A Guglielmi, G L Frassineti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2015
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
E Van Cutsem, H Prenen, G D'Haens, et al.
ESMO Open
|
December 1, 2016
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
N I Cherny, R Sullivan, U Dafni, et al.
Oncology Reports
|
January 12, 2005
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium
Vito Lorusso, Enrico Crucitta, Nicola Silvestris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A Sobrero, A Grothey, T Iveson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
R Labianca, A Sobrero, L Isa, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
Oncology
|
July 15, 2005
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
M Scartozzi, A Sobrero, G Gasparini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 24, 2019
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials
S Cascinu, D Poli, A Zaniboni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2007
First-line single-agent cetuximab in patients with advanced colorectal cancer
A Pessino, S Artale, S Sciallero, et al.
British Journal of Cancer
|
December 7, 2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
S Cascinu, R Berardi, S Salvagni, et al.
British Journal of Cancer
|
February 14, 1998
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study
C Aschele, A Guglielmi, G L Frassineti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2015
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
E Van Cutsem, H Prenen, G D'Haens, et al.
ESMO Open
|
December 1, 2016
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
N I Cherny, R Sullivan, U Dafni, et al.
Oncology Reports
|
January 12, 2005
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium
Vito Lorusso, Enrico Crucitta, Nicola Silvestris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A Sobrero, A Grothey, T Iveson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
R Labianca, A Sobrero, L Isa, et al.
Page
of 7